Printer Friendly

Primagen Scientists Discover a New Virus, File for European Patent.

AMSTERDAM, Netherlands -- AMSTERDAM, Netherlands, June 10 /PRNewswire/ -- Primagen Holding BV (http://www.primagen.com/) scientists in collaboration with the Department of Human Retrovirology of the Academic Medical Center, University of Amsterdam have identified a new virus, belonging to the family of enteroviruses. The new virus is subject of a European Patent application entitled, "New enterovirus, vaccines, medicaments and diagnostic kits."

Primagen's virus discovery program is built on its new proprietary methodology and the newly identified enterovirus is the first new virus identified using this method. "The finding of the new virus is an exhilarating event," states Dr. Bob van Gemen, Primagen's CEO. "But even more important than the finding of the new virus is the fact that the current success proves the discovery power of the methodology developed by Primagen. We feel that this discovery should be made readily available and we will share it with others and encourage researchers to contact us about using this virus."

"Next to expansion of the phylogenetic tree with this new virus, our discovery algorithm also allows the design of diagnostic tests detecting whole families of viruses and their variants. Our technology is applicable to many of the viral families that encompass viral species currently under investigation such as newly emerging pathogens, like SARS and potential terror agents, like Ebola and Smallpox" adds Dr. Peter van den Broek, senior scientist and project manager of the virus discovery program at Primagen.

About Primagen

Primagen Holding B.V. is a privately held company headquartered in Amsterdam, The Netherlands. Primagen designs, develops and commercializes molecular tests that have high, individualized predictive value and improve the quality of life for patients suffering from life-threatening diseases, such as infections, AIDS and cancer. Primagen's success is built on a unique combination of an international scientific network and excellent capabilities for product development, manufacturing and marketing. The company is solution-driven and selects those leads for potential products that add to the improvement of therapy management. Primagen markets two molecular tests; Retina(TM) Mitox measures mitochondrial DNA and RNA in clinical samples, with unmatched accuracy, to predict toxic side effects of treatment. Retina(TM) Rainbow enables detection of all circulating HIV-1 subtypes and combined with Primagen's proprietary dried bloodspot technology helps to bring HIV-1 virus testing to resource-poor countries.

CONTACT: Bob van Gemen, CEO of Primagen Holding BV, +31-20-5668576, b.vangemen@primagen.com

Web site: http://www.primagen.com/
COPYRIGHT 2003 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Geographic Code:4EUNE
Date:Jun 10, 2003
Words:397
Previous Article:What's So Groundbreaking about Merchandise Optimization? ProfitLogic Explains How Retailers Can Make More Profitable, Predictable and Efficient...
Next Article:Cabela's Chooses RightNow for Online Customer Service; Hosted Application Model and Proven Record of Success Key Factors in Leading Catalog/Web...


Related Articles
Primagen Sponsors Global Immunity With HIV-1 Tests For South African AIDS Clinic.
Primagen and UMC, Utrecht Join Forces to Strengthen Virus Discovery Program.
Exponential Biotherapies Opens Phage Service Center in Amsterdam in Collaboration with Primagen.
Focus Diagnostics - First U.S. Laboratory to License Newly Discovered Coronavirus CoV-NL63 From Primagen.
Focus Diagnostics - First U.S. Laboratory to License Newly Discovered Coronavirus CoV-NL63 From Primagen.
Focus Diagnostics licenses coronavirus CoV-NL63 from Primagen.
Primagen Licenses Newly Discovered Coronavirus CoV-NL63 to bioMerieux.
Primagen Licenses Newly Discovered Coronavirus CoV-NL63 to bioMerieux.
Primagen Virus Discovery Group Chosen for EU-funded GRACE Network of Excellence.
Primagen Virus Discovery Group Chosen for EU-funded GRACE Network of Excellence.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters